Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1498 | FTX-6058 oral capsule(s) / Midazolam Syrup Wiki | 1.00 |
| drug1499 | FTX-6058/placebo oral capsule(s) Wiki | 1.00 |
| drug2487 | NORS (Nitric Oxide Releasing Solution) Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a study to evaluate the safety, tolerability and pharmacokinetics of FTX-6058 in healthy adult subjects.
Description: To evaluate the safety and tolerability of FTX-6058, the incidence of treatment-emergent adverse events will be assessed by clinically significant laboratory test results, ECGs, and vital signs.
Measure: Treatment-Emergent Adverse Events Time: Up to approximately 4 weeks of monitoringDescription: Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry.
Measure: Plasma Concentrations of FTX-6058 Time: Study Part A: Days 1 and 2Description: Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry
Measure: Plasma Concentrations of FTX-6058 Time: Study Part B: Days 1, 2, 7, 8, and 12-15Description: Change from baseline in H3K27me3/Total Histone H3 ratio in circulating monocytes will be evaluated by fluorescence-activated cell sorting (FACS).
Measure: Target Engagement of FTX-6058 Time: Study Part B: Days 1, 2, 7-10 and 14Description: Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry.
Measure: Plasma Concentrations of FTX-6058 Time: Study Part C: Days 1 and 2Description: Blood samples will be collected to measure the plasma concentration of FTX-6058 at specified timepoints by liquid chromatography with tandem mass spectrometry .
Measure: Plasma Concentrations of FTX-6058 Time: Study Part D: Days 11, 12 and 13Description: Blood samples will be collected to measure the plasma concentration of Midazolam at specified timepoints by liquid chromatography with tandem mass spectrometry
Measure: Plasma Concentrations of for Midazolam Time: Study Part D: Days 1, 2, 12 and 13Description: Blood samples will be collected to measure the plasma concentration of 1-OH-Midazolam at specified timepoints by liquid chromatography with tandem mass spectrometry.
Measure: Plasma Concentrations of for 1-OH-Midazolam Time: Study Part D: Days 1, 2, 12 and 13Description: A model of the relationship between time-match FTX-6058 plasma concentrations QTc intervals may be developed and will include simulations to predict potential QT risk.
Measure: Predictive Model of the Relationship between QTc Interval and FTX-6058 Concentration Time: Study Part A: Days 1 and 2 and Study Part B: Days 1, 2, and 7-15Description: Change from baseline in the percentage of F reticulocytes, a fetal hemoglobin pharmacodynamic biomarker that may be measured in peripheral whole blood by flow cytometry.
Measure: Change in F Reticulocytes Time: Study Part B: Days 1, 7, 14 and 7-10 days after last dose of study drug.Description: Change from baseline in the globin gene mRNA, a fetal hemoglobin pharmacodynamic biomarker that may be measured in peripheral whole blood by digital drop polymerase chain reaction (ddPCR).
Measure: Change in Globin Gene mRNA Time: Study Part B: Days 1, 7, 14 and 7-10 days after last dose of study drug.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports